You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Pirfenidone gel in patients with localized scleroderma: a phase II study
|
|---|---|
| Published in |
Arthritis Research & Therapy, December 2014
|
| DOI | 10.1186/s13075-014-0510-4 |
| Pubmed ID | |
| Authors |
Marco Rodríguez-Castellanos, Alberto Tlacuilo-Parra, Sergio Sánchez-Enríquez, Ezequiel Vélez-Gómez, Elizabeth Guevara-Gutiérrez |
| Abstract |
IntroductionLocalized scleroderma is an inflammatory disease in its first stages and a fibrotic process in later stages, principally mediated by the transforming growth factor beta (TGF-ß). To date there is no standard treatment. The objective of this study was to determine the effectiveness and safety of 8% pirfenidone gel in patients with localized scleroderma.MethodsThis was an open phase II clinical trial that included 12 patients. Treatment with pirfenidone was indicated, three times a day for six months. Patients were evaluated clinically with the modified Localized Scleroderma Skin Severity Index (mLoSSI), as well with a durometer and histologically using hematoxylin-eosin and Masson¿s trichrome stains.ResultsThe baseline mLoSSI average was 5.83¿±¿4.80 vs. 0.83¿±¿1.75 (P¿=¿0.002) at six months. The initial durometer induration of the scleroderma plaques was 35.79¿±¿9.10 vs. 32.47¿±¿8.97 at six months (p¿=¿0.05). We observed histopathological improvement with respect to epidermal atrophy, inflammation, dermal or adipose tissue fibrosis, and annex atrophy from 12.25¿±¿3.25 vs. 9.75¿±¿4.35 (p¿=¿0.032). The 8% pirfenidone gel application was well tolerated and no side effects were detected.ConclusionsThis is the first study on the therapeutic use of pirfenidone gel in localized scleroderma. It acts on both the inflammatory and the fibrotic phases. Considering its effectiveness, good safety profile, and advantage of topical application, pirfenidone is a treatment option in this condition. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 29% |
| United States | 2 | 29% |
| United Kingdom | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 20% |
| Other | 7 | 14% |
| Student > Master | 6 | 12% |
| Student > Bachelor | 4 | 8% |
| Student > Postgraduate | 4 | 8% |
| Other | 8 | 16% |
| Unknown | 10 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Agricultural and Biological Sciences | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Business, Management and Accounting | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 13 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2021.
All research outputs
#5,239,459
of 25,368,786 outputs
Outputs from Arthritis Research & Therapy
#1,227
of 3,380 outputs
Outputs of similar age
#67,916
of 359,194 outputs
Outputs of similar age from Arthritis Research & Therapy
#18
of 56 outputs
Altmetric has tracked 25,368,786 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,194 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.